Treatment with 250 mg kg−1 (b.i.d.)SynacinnTM of the streptozotocin-induced type 1 diabetic rats significantly (p < 0.05) improved the fasting blood glucose (59%), triglyceride (58%), cholesterol (47%), alanine aminotransferase (60%), alkaline phosphatase (90%), and creatinine (32%) levels. The gene discussed is GPT; the disease is type 1 diabetes mellitus.